Predict your next investment

HEALTHCARE | Biotechnology
kiniksa.com

See what CB Insights has to offer

Stage

IPO | IPO

Date of IPO

5/25/2018

Market Cap

0.93B

Stock Price

14.50

About Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering or acquiring, developing, and commercializing therapeutic medicines for patients suffering from devastating and debilitating diseases with significant unmet medical need.

Kiniksa Pharmaceuticals Headquarter Location

Clarendon House 2 Church Street

Hamilton, HM 11,

Bermuda

781-431-9100

Latest Kiniksa Pharmaceuticals News

Kiniksa Pharmaceuticals to Report Second Quarter 2021 Financial Results on August 3, 2021

Jul 20, 2021

HAMILTON, BERMUDA HAMILTON, Bermuda, July 20, 2021 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, August 3, 2021 at 8:30 a.m. Eastern Time to report its second quarter 2021 financial results and recent corporate and portfolio activity. A live webcast will be accessible through the Investors & Media section of the company’s website at www.kiniksa.com . A replay of the webcast will be available on Kiniksa’s website for 14 days following the conference. The conference call can be accessed by dialing (866) 614-0636 (U.S. and Canada) or (409) 231-2053 (international) using conference ID number 1485623. About Kiniksa Kiniksa is a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Kiniksa’s portfolio of assets, ARCALYST® (rilonacept), mavrilimumab, vixarelimab and KPL-404, are based on strong biologic rationale or validated mechanisms, target underserved conditions and offer the potential for differentiation. These assets are designed to modulate immunological pathways across a spectrum of diseases. For more information, please visit  www.kiniksa.com . ARCALYST® is a registered trademark of Regeneron Pharmaceuticals, Inc. Every Second Counts!™

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Kiniksa Pharmaceuticals Patents

Kiniksa Pharmaceuticals has filed 8 patents.

The 3 most popular patent topics include:

  • Immunology
  • Clusters of differentiation
  • Cytokines
patents chart

Application Date

Grant Date

Title

Related Topics

Status

4/11/2018

12/3/2019

Monoclonal antibodies, Fluid dynamics, Molecular biology, Proteins, Protein methods

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

4/11/2018

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Grant Date

12/3/2019

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Monoclonal antibodies, Fluid dynamics, Molecular biology, Proteins, Protein methods

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Kiniksa Pharmaceuticals Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Kiniksa Pharmaceuticals Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.